Cardiometabolic diseases remain one of the leading causes of death, loss of healthy life years, and healthcare expenditure.

Although the optimal use of established therapies would already allow for the effective prevention of most of these conditions, a proportion of patients continues to show partial resistance to treatment or inadequate disease control.

In recent years, we have witnessed a profound shift in cardiovascular risk assessment—with the identification of numerous new risk factors—and, even more importantly, in prevention and therapeutic strategies.

The therapeutic armamentarium for treating severe familial dyslipidaemias, achieving very low lipid targets, and managing diabetes, obesity, resistant hypertension, and heart failure has expanded with innovative agents featuring mechanisms of action markedly different from conventional therapies.

Evidence-based optimization of standard treatments, combined when appropriate with next-generation therapies, requires continuous updates, training, and renewed commitment—particularly in view of the current and upcoming structural and organizational transformations within the national healthcare system.

The third edition of this advanced course will feature contributions from young nationally and internationally recognized experts, as well as insights and real-world experiences shared by young clinicians engaged in daily practice